Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced…
Month: May 2022
Outlook Therapeutics to Participate in Retina World Congress 2022
ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or…
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian…
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC)…
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:…
The Greenrose Holding Company to Present at Upcoming May Investor Conferences
AMITYVILLE, N.Y., May 10, 2022 (GLOBE NEWSWIRE) — The Greenrose Holding Company Inc. (OTC: GNRS,…
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization…
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May…
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc’s CannAmide™ with Clearmind’s MEAI has the potential…
Opthea Presentation at The Retina World Congress 2022
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage…
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
Data from the completed Phase 1b/2 trial to be presented at the American Society of…
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Enlivex Announces Upcoming May Conference Presentations
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin)…
Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatment
NEW ORLEANS, May 10, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or the “Company”),…
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET BRIDGEWATER, N.J., May 10, 2022…